Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROPAMIDE versus GLUCAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROPAMIDE versus GLUCAMIDE.
CHLORPROPAMIDE vs GLUCAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels, increasing intracellular calcium, and enhancing peripheral insulin sensitivity. Also reduces hepatic glucose production.
Glucamide (glyburide) is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (K-ATP), leading to membrane depolarization, calcium influx, and exocytosis of insulin. It may also increase peripheral insulin sensitivity and reduce hepatic glucose production.
Initial: 250 mg orally once daily. Maintenance: 100-500 mg orally once daily.
50 mg orally twice daily, increased to 100 mg twice daily after 4 weeks if tolerated
None Documented
None Documented
Clinical Note
moderateChlorpropamide + Gatifloxacin
"Chlorpropamide may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateChlorpropamide + Rosoxacin
"Chlorpropamide may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateChlorpropamide + Levofloxacin
"Chlorpropamide may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateChlorpropamide + Trovafloxacin
36 hours (range 25-60 hours). Prolonged in renal impairment due to cumulative effects and hypoglycemia risk.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 12-18 hours in moderate renal impairment (CrCl 30-60 mL/min) and up to 24-36 hours in severe renal impairment (CrCl <30 mL/min); clinical context: duration of hypoglycemic effect correlates with half-life in renal impairment.
Renal excretion of unchanged drug (80-90%) and hepatic metabolites (10-20%). Biliary/fecal excretion is minimal (<5%).
Primarily renal excretion of unchanged drug (70-80%) and glucuronide conjugate (10-15%); biliary/fecal excretion accounts for 5-10%.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic
"Chlorpropamide may increase the hypoglycemic activities of Trovafloxacin."